The Patent Finder

Avencell Europe GmbH

9 patents currently held · Updated Nov 19, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Sep 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jun 1, 2027
    The maintenance fee for Antibodies against prostate-specific stem cell antigen and use thereof (US 9,200,078) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
  • 1 fee due Oct 7, 2027
    The maintenance fee for Universal Chimeric Antigen Expressing Immune Cells for Targeting of Diverse Multiple Antigens and Method of Manufacturing the Same and Use of the Same for Treatment of Cancer, Infections and Autoimmune Disorders (US 10,611,814) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 21, 2026
  • 1 term has ended since Aug 21, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,759,494ANTI-CD33 Antibodies and Use Thereof for Immunotargeting in Treating CD33-Associated Illnesses
In force
 · High confidence
In forceHigh confidence
US 10,246,516Anti-La Antibodies and Their Use for Immunotargeting
In force
 · High confidence
In forceHigh confidence
US 9,200,078Antibodies against prostate-specific stem cell antigen and use thereof
In force
 · High confidence
In forceHigh confidence
US 9,540,446Anti-La Antibodies and Their Use for Immunotargeting
In force
 · High confidence
In forceHigh confidence
US 10,611,814Universal Chimeric Antigen Expressing Immune Cells for Targeting of Diverse Multiple Antigens and Method of Manufacturing the Same and Use of the Same for Treatment of Cancer, Infections and Autoimmune Disorders
In force
 · High confidence
In forceHigh confidence
US 10,766,943Universal Chimeric Antigen Expressing Immune Cells for Targeting of Diverse Multiple Antigens and Method of Manufacturing the Same and Use of the Same for Treatment of Cancer, Infections and Autoimmune Disorders
In force
 · High confidence
In forceHigh confidence
US 12,747,277Universal Chimeric Antigen Expressing Immune Cells for Targeting of Diverse Multiple Antigens and Method of Manufacturing the Same and Use of the Same for Treatment of Cancer, Infections and Autoimmune Disorders
In force
 · High confidence
In forceHigh confidence
US 12,173,063Targeting Modules for Universal Chimeric Antigen Receptor Expressing Immune Cells and Use in the Treatment of Cancer, Infections and Autoimmune Disorders
In force
 · High confidence
In forceHigh confidence
US 11,560,426Targeting Modules for Universal Chimeric Antigen Receptor Expressing Immune Cells and Use in the Treatment of Cancer Infections and Autoimmune Disorders
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 9: 2 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited